Mahdere Asfaw, MD
Endocrinology, Diabetes & Metabolism · Salem, VANPI 1083797047
Payments from drug & device makers
Across 161 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$482
- IBSA Pharma Inc.$315
- Novo Nordisk$291
- Amgen$253
- Xeris Pharmaceuticals, Inc.$240
- Abbott$210
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,18398%
- Education$642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 21 | $482 |
| IBSA Pharma Inc. | 14 | $315 |
| Novo Nordisk | 17 | $291 |
| Amgen(2 entities) | 13 | $253 |
| Xeris Pharmaceuticals, Inc. | 11 | $240 |
| Abbott | 9 | $210 |
| Boehringer Ingelheim | 15 | $198 |
| Sanofi-aventis U.S. LLC | 8 | $160 |
| Lifescan, Inc. | 6 | $156 |
| Insulet Corporation | 6 | $127 |
| Tandem Diabetes Care, Inc. | 4 | $89 |
| Bayer | 4 | $83 |
| Amneal Pharmaceuticals LLC | 5 | $81 |
| Averitas Pharma Inc. | 3 | $59 |
| Medtronic(2 entities) | 3 | $49 |
| Neurelis, Inc. | 3 | $49 |
| Corcept Therapeutics | 2 | $45 |
| AbbVie | 2 | $39 |
| AstraZeneca | 2 | $39 |
| Intuity Medical Inc | 1 | $31 |
| Johnson & Johnson | 1 | $30 |
| Lundbeck LLC | 1 | $26 |
| Novartis | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Cardinal Health 414 LLC | 1 | $22 |
| Merck | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| BD | 1 | $21 |
| Valeritas, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
How this compares
$3,247 in reported general payments places this provider in the 60th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 151 | $231,716 |
| OzempicSemaglutide | 84 | $160,015 |
| JardianceEmpagliflozin | 89 | $117,489 |
| MounjaroTirzepatide | 43 | $63,496 |
| FarxigaDapagliflozin Propanediol | 47 | $58,018 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 30 | $56,494 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $44,060 |
| RybelsusSemaglutide | 15 | $29,072 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $23,377 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,575 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $20,165 |
| Humalog Kwikpen U-100Insulin Lispro | 49 | $18,134 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $18,048 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $16,942 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 113 | $14,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $482 | $295,213194 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $291 | $198,663129 claims |
| Boehringer IngelheimJardiance | $198 | $117,48989 claims |
| AstraZenecaFarxiga | $39 | $58,01847 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $160 | $46,68745 claims |
| AbbVieSynthroid | $39 | $4,74658 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $81 | $2,271238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Salem
- Ali IranmaneshSalem$1.1M
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
- Samamtha HudsonMidlothian$372K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.